Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cance...(y one patient dying (at36.4 months). Ove...),Health

o 8 of 19 patients are still alive (ranging from 24.5 months to 92

months), with median overall survival in all patients of 33.8 months

(p < 0.0079) (the "p value" measures the likelihood that the observed

clinical effect is due to chance: a 'p' value of 0.0079 means that

there is a less than 1% possibility that the longer survival time of

DCVax(R)-Brain-treated patients is due to chance);

o 5 of the 8 patients who are still alive show no signs of cancer

recurrence, with follow-up time ranging from 41 months to 92 months;

o The median time to progression (i.e. tumor recurrence) is 18.1 months,

compared to 8.1 months for patients treated at UCLA during the same

time period (p = 0.00001);

o 90% of patients have surpassed the Standard of Care median time to

progression of 8.1 months;

o 84% of patients have surpassed the Standard of Care median overall

survival time of 17.0 months;

o To date, 68% of patients receiving DCVax(R)-Brain in addition to

Standard of Care have lived longer than 2 years, 42% have lived longer

than 3 years, and 26% have lived longer than 4 years (48, 54, 57, 62

and 92 months so far);

"Findings such as these, where we are seeing 68% of our DCVax(R)-Brain-treated patients with GBM alive after two years, and 26% alive for more than 4 years (and counting) reinforce our belief that DCVax(R)-Brain may make a significant difference in the lives of patients with GBM," stated Dr. Alton L. Boynton, President and Chief Executive Officer of Northwest Biotherapeutics. "We believe that the results to date are particularly striking, and we plan to give patients continued booster injections at 3 month intervals. We believe that these booster injections will further enhance and sustain the pa
'/>"/>